Colostrum as Oral Immune Therapy to Promote Neonatal Health
Sheila M. Gephart, PhD, RN; Michelle Weller, BSN, RN, IBCLC necrotizing enterocolitis (NEC) all share a common beginning in an immature and exaggerated inflammatory response. However, premature infants have a treatment available to them that other critically ill adult patients do not-their own mother's milk, beginning with colostrum. Own mother's colostrum (OMC) provides an immune therapy to stimulate the development and response of the neonatal immune system. 2 Human milk feeding, particularly if exclusive in the first 14 to 28 days of life, reduces neonatal complications by improving progression to enteral feeding and delivering powerful immuneboosting nutrition. [3] [4] [5] Very low-birth-weight (VLBW) infants unable to feed orally can still receive immunologic benefits of colostrum unless breast milk is contraindicated. Contraindication to breast milk feeding is rare and even controversial. In the United States, it is recommended that a mother with human immunodeficiency virus (HIV/AIDS) or human T-cell ly mphotropic virus type 1 (HTLV-1) should not breastfeed or provide When infants are fed via nasal gastric tube, the immune benefits of human milk bypass the or alpharyngeal mucosa-associated lymphoid tissue. When given oropharyngeally, cytokines in the OMC interact with lymphoid cells in the lymphoid tissue in the mouth. Absorbing the immunologic factors via the oral mucosa stimulates the immune system systemically and promotes the mucosal differentiation in the gut and thus, developing the protective gut immune barrier. St imulation of both the oralpharyngeal mucosa-associated lymphoid tissue and the gut-associated lymphoid tissue is important to best overall immune development.
Lactoferrin is an important protein present in high concentrations in colostrum; these levels are even higher when a mother delivers prematurely. 12 Lactoferrin, a glycoprotein and oligosaccharide (ie, prebiotic) found in colostrum, supports the innate immune response to maintain a wide range of physiologic norms. 13 It has antimicrobial, anti-inflammatory, and immunomodulatory functions. Interestingly, lactoferrin binds to iron, preventing pathogenic organisms from obtaining iron from the infant necessary for their survival. 12, 14, 15 There have been several small clinical trials showing that lactoferrin decreases the incidence of lower respiratory tract infections, the duration of dehydrating diarrhea, the severity of rotavirus infection, and the colonization with giardia in infants. 14, [16] [17] [18] [19] Despite the significant evidence of the benefit of human milk for this vulnerable population, lactation rates for these infants in the NICU are limited. 20 No parent is prepared to have their newborn cared for in the NICU. It is extremely difficult to maintain the necessary pumping regimen needed to ensure adequate milk production when parents cannot freely touch or hold their newborn. In addition to being concerned on a daily basis for the life of her infant, a mother must rely on a mechanical breast pump, pumping at least 8 times each day to establish and maintain an adequate milk supply.
PROCEDURE FOR COLOSTRUM AS ORAL IMMUNE THERAPY
A proposed solution to early exposure of human milk to neonates in the NICU is to use OMC as oral immune therapy. A sample "colostrum as oral immune therapy" (C-OIT) protocol is shown in Table 1 , derived from assembling the protocols of the studies in this review. Oropharyngeal administration of OMC is not given as an enteral feeding and is in such small volumes that the infant does not need to swallow. A small amount of milk (typically 0.2 mL divided between 2 cheeks) is placed on the oral mucosa in the buccal cavity for absorption. A sterile cotton swab or oral applicator is used for each application of human milk. A caregiver, preferably the parent, gently paints the inside of the mouth, breast milk for her infant although the recommendation differs in less-developed countries with less access to clean water and formula supplements. Other viral illnesses in the mother such as chicken pox, hepatitis B and C, herpes simplex, and cy tomegalovirus should be evaluated on an individual basis, depending on when the mother acquires the virus and where the lesions occur. An infant diagnosed with galactosemia should not receive breast milk. 6 A sometimes-devastating infection that preterm and high-risk neonates are vulnerable to is NE C; however, implementation of prevention practices could reduce NEC by at least half. 7 A recently developed evidence-based bundle designed to increase human milk feeding in California NICUs demonstrated a statistically significant impact on NEC rates when oral immune therapy using colostrum, preferential feeding of human milk, and use of standardized feeding protocols were implemented together. 8 The importance of human milk in the management of preterm and high-risk neonates is well documented and recommended by the American Academy of Pediatrics, with colostrum being the perfect first immune stimulator in infants. 9 Human milk, in addition to being the perfect species-specific nutrition for an infant, contains many types of protective agents. Colostrum is the milk produced in the first few days after birth when the tight junctions in the mammary epithelium are open. Open tight junctions allow for transport of many more immune components from the mother's circulation into the milk. 10 Human milk changes in response to antigens the mother is exposed to or immunized against. These antigens allow lymphocytes in the breast to secrete immunoglobulin into the milk. 6 Therefore, the more a mother visits and holds her hospitalized infant skin to skin (kangaroo care), the more likely her breast milk will provide unique specific protection to her infant. 6 
BIOLOGIC PLAUSIBILITY FOR COLOSTRUM AS ORAL IMMUNE THERAPY
The unique properties of human milk provide the neonate with "immunologic, anti-infective, antiinflammatory, epigenetic, and mucosal membrane protecting properties." 11(p217) Human colostrum has higher concentrations of secretory IgA, growth factors, lactoferrin, anti-inflammatory cytokines, oligosaccharides, antioxidants, and other protective components as compared with mature human milk.
In a theoretical paper describing the foundation for how colostrum works as immune therapy, Rodriguez et al 2 described in detail how the composition of colostrum stimulates the immature neonatal immune system by a pr ebiotic mechanism. Through lymphoid tissue in the oropharynx and the gut, colostrum stimulates immune development.
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Gephart and Weller including the tongue, gums, and buccal area. Fresh colostrum is ideal and should be used whenever possible. Proper identifiers are a must to ensure that the patient receives only the milk of the biologic mother. Most tested protocols provide oral care with human milk every 3 to 4 hours.
CLINICAL QUESTION AND SEARCH STRATEGY
To answer the clinical question, "In critically ill neonates does oral immune therapy with colostrum compared with usual care without colostrum positively impact outcomes (eg, complication rates, time to full feedings, the number of feeding interruptions, and immune response)," a search of the literature was completed. The outcome in question was kept broad to reflect multiple potential benefits. Research articles were searched using several databases including CINAHL, Cochrane, PsycInfo, and PubMed. Terms used for the search included colostrum, neonate, neonatal intensive care, oral immune therapy, buccal care, and oropharyngeal administration of colostrum. Articles were retained if they had been published in the last 10 years, were reporting an original research study, and had full-text English language available. On the basis of these criteria, 5 research reports were retained. [21] [22] [23] 25, 26 Very few studies were identified using this search strategy. To ensure a comprehensive search, dissertation abstracts indexed in ProQuest and conference pro- 
RESULTS

Study Quality
Overall, study quality was fair. Studies identified in the search included 2 feasibility trials, 21 ,22 2 small randomized controlled trials, 23 ,24 2 pre-/postcohort studies, 25, 26 and 1 study in which C-OIT was studied as part of a feeding protocol. 27 The studies differed in the dosing frequency for oral immune therapy (eg, every 2 hours, every 3-4 hours, and every 4 hours), the duration of treatment, and the outcomes measured. Duration of therapy ranged from 48 hours 23 to 7 days. 21 Adherence to the intervention (ie, the number of daily doses of C-OIT) was incompletely measured, potentially explaining marginal effects. Small study samples were used, likely potentiating the inability to detect a group difference if they existed (ie, leading to a type II error likely with underpowered studies with small samples). Another limitation is that 2 of the studies were published in a journal with limited peer review, 21, 23 1 study was a dissertation, 24 and a final study was a peer-reviewed conference abstract. 27 
Study Findings and Strength of Evidence
Overall, C-OIT is safe and feasible with very low to no risk associated with the intervention. 21, 22 Infants who received C-OIT began enteral feedings sooner and were less likely to be growth restricted at 36 weeks' po stmenstrual age. In at least 1 study, when C-OIT was administered as part of a feeding protocol, the number of to tal parenteral nutrition days and total parenteral nutrition-related outcomes were impacted. 27 Across the studies, small sample sizes yielded low statistical power and no differences were identified in infectious outcomes like NEC and VAP. Study results are summarized in Table 2 . 
Results
Study Limitations Strengths
Caprio et al, 2013 27 Northeast,
the United States
Descriptive pre-/ posttest after a feeding protocol was initiated including C-OIT in a single center Infants Lower maximum direct bilirubin levels (P < .01).
Lower maximum alkaline phosphatase (P < .0005).
32% reduction in infants discharged small for gestational age (P < .007).
No significant difference noted in lab draws, late onset sepsis, and NEC. 
IMPLICATIONS FOR PRACTICE
At this time, the theoretical explanation for how C-OIT acts to stimulate the immune response is supported by preclinical and early clinical studies. It appears to be safe and feasible. Although strong evidence about its impact on clinical outcomes is lacking, it poses little risk to infants. When parents administer OMC, they appear to enjoy the process and time to connect with their infant. 28 It is undeniably important for mothers to begin expressing their milk very early in the NICU stay to sustain their long-term supply, making any encouragement they can derive from the process invaluable.
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IMPLICATIONS FOR RESEARCH
Undeniably, there is theoretical and preclinical support for this practice but more real-world clinical studies with vulnerable infants are needed. Like Rodriguez and colleagues' study, 23 immune outcomes can be measured, particularly urine secretory IgA and urine lactoferrin. Examining cytokine levels for infants receiving C-OIT compared with those who do not could strengthen our understanding of how C-OIT impacts the immune response. Challenges in conducting these studies will be to account for confounders as covariates in the statistical models and to ethically consider how randomization is best carried out.
Without a doubt, well-designed randomized controlled trials will provide the most definitive evidence for C-OIT's effects. However, given the preclinical evidence and the very high cost risks of not providing immune stimulation (eg, sepsis and NEC), it can be argued that randomly assigning infants to a control when mothers wish to provide colostrum is not ethical. Given the early stage of the evidence base, a Both the dose and proportion of enteral feeding is important to reduce neonatal morbidity.
Colostrum is the first human milk mothers produce. It contains vital immune stimulating components that premature infants lack.
11,13
When C-OIT is used, time to full enteral feedings is reduced. 23, 25 When C-OIT is combined with a standardized feeding protocol, impacts are greater. 27 
Evidence is unclear
What is the impact of C-OIT on morbidity outcomes such as necrotizing enterocolitis, sepsis, retinopathy of prematurity or chronic lung disease?
What is the optimal dose and duration of C-OIT?
What is the impact of C-OIT for critically ill infants > 1500 g (eg, congenital heart disease, birth defects)?
How does neonatal inflammatory response change (eg, measured using cytokine levels) after C-OIT?
Is C-OIT more protective than other oral care products (eg, Biotene) for ventilatorassociated infection prevention?
What we need to study
Inflammatory marker response to C-OIT.
C-OIT in infants > 1500 g who are critically ill.
Effects of C-OIT using comparison groups either using an experimental design or time series designs with historical controls. Another option is to use case-control designs with matching based on gestational age, birth weight, race, severity of illness.
What we can do today Encourage mothers to provide human milk within the first 4 h of delivery.
Share the science of human milk with parents, describing it as an immune therapy (not solely nutrition).
9-11
Help the parents to keep track of the volume and frequency of human milk expression and praise their success. 10 Continually support parents and advocate for "never-fail" and "always use" of human milk for all infants. [28] [29] [30] Give human milk in the order it was pumped.
11
Use creative approaches to support human milk use in the NICU.
30,31
Abbreviations: C-OIT, colostrum as oral immune therapy; NICU, neonatal intensive care unit.
contrary argument is that we absolutely need that level of evidence to move forward to offer this therapy to infants on a broader scale. Such considerations will need to be taken in the design of such studies. If quasiexperimental studies are conducted, a strong approach is to identify a comparison group, match by gestational age and/or weight, and compare outcomes from pre-and postimplementation of C-OIT practice. In that case, considering confounders like severity of illness and provision of overall dose of human milk over the clinical course would strengthen interpretation of findings from such studies.
CONCLUSION
Increasing the exposure of human milk to neonates in the NICU setting must become standard of practice, yet the evidence-supported effects of early colostrum is still a topic for study (see Table 3 for a summary of key points). Early exposure to even small amounts of mother's milk significantly reduces the use of parenteral fluids, decreases the risk of infection, and lessens the duration of hospitalization without adverse effect. 29 Evidence suggests that when healthcare providers convey the importance of human milk for infants, it empowers parents to support a pumping regimen to maintain a milk supply for their infant. 11, 30 In an environment where a parent often has very little direct control over the care of their infant, providing human milk allows a significant contribution by the mother. More studies are needed to demonstrate a correlation between the use of human milk for oral care and the potential immune effects against infections, especially NEC.
